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Background-—The C2HEST score (coronary artery disease or chronic obstructive pulmonary disease [1 point each]; hypertension
[1 point]; elderly [age ≥75 years, 2 points]; systolic heart failure [2 points]; thyroid disease [hyperthyroidism, 1 point]) was
initially proposed for predicting incident atrial ﬁbrillation (AF) in the general population. Its performance in poststroke patients
remains to be established, especially because patients at high risk for incident AF should be targeted for more comprehensive
screening. This study aimed to evaluate this newly established incident AF prediction risk score in a post–ischemic stroke
population.
Methods and Results-—Validation was based on a hospital-based nationwide cohort with 240 459 French post–ischemic stroke
patients. Kaplan–Meier curves for incident rate of AF depict differences between varying risk categories. Discrimination of the
C2HEST score was evaluated using the C index, the net reclassiﬁcation index, integrated discriminatory improvement, and decision
curve analysis. During 7.911.5 months of follow-up, 14 095 patients developed incident AF. The incidence of AF increased from
23.5 per 1000 patient-years in patients with a C2HEST score of 0 to 196.8 per 1000 patient-years in patients with a C2HEST score
≥6. Kaplan–Meier curves showed a clear difference among different risk strata (log-rank P<0.0001). The C2HEST score had good
discrimination with a C index of 0.734 (95% CI, 0.732–0.736), which was better than the Framingham risk score and the CHA2DS2-
VASc score (congestive heart failure, hypertension, age ≥75 [doubled], diabetes mellitus, stroke [doubled], vascular disease, age 65
to 74 years, and female sex) (P<0.0001, respectively). The C2HEST score was also superior to the Framingham risk score and the
CHA2DS2-VASc score as shown by the net reclassiﬁcation index, integrated discriminatory improvement (P<0.0001, respectively)
and decision curve analysis.
Conclusions-—The C2HEST score performed well in discriminating the individual risk of developing incident AF in a white European
population hospitalized with previous ischemic stroke. This simple score may potentially be used as a risk stratiﬁcation tool for
decision making in relation to a screening strategy for AF in post–ischemic stroke patients. ( J Am Heart Assoc. 2019;8:e012546.
DOI: 10.1161/JAHA.119.012546.)
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A trial ﬁbrillation (AF) is the most common sustainedarrhythmia, with increasing prevalence and incidence
worldwide.1–4 Many AF patients are asymptomatic or have
nonspeciﬁc symptoms, and a large proportion remain undi-
agnosed.5 These asymptomatic patients may at higher risks of
thromboembolic events and mortality compared with patient
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who have symptoms.6 Some would be identiﬁed with AF only
after their presentation with a major complication, such as
stroke or heart failure (HF).7
Individual risk evaluation for developing incident AF is
important for the decision-making process of early primary
prevention and detection of AF, whichmay associatewith better
outcomes.8 A simple clinical risk-evaluation tool may facilitate
effective and cost-effective prevention and screening strategies
for incident AF. Such a tool may help identify patients at high
risk for incident AF who can be targeted for more intensive
screening programs and primary prevention strategies.
A simple clinical risk-stratiﬁcation model, the C2HEST
score (coronary artery disease or chronic obstructive pul-
monary disease [1 point each]; hypertension [1 point]; elderly
[age ≥75 years, 2 points]; systolic HF [2 points]; thyroid
disease [hyperthyroidism, 1 point]) was recently proposed to
predict incident AF among Asian patients.9 This score was
derived from a large cohort of 471 446 Chinese patients10
and was validated in the Korean National Health Insurance
Service Health Screening cohort with 514 764 Korean
patients.11 The risk of incident AF increased signiﬁcantly with
higher C2HEST score.
9
Current guidelines recommend that poststroke patients
need AF screening.12 However, diverse screening approaches
may have different capabilities in detecting unrevealed AF;
perhaps more aggressive screening methods should be used
for patients who are more likely to develop incident AF,13
enabling an effective and cost-effective screening strategy.
The present study aimed to assess whether the newly
established risk model, the C2HEST score, could predict AF
in patients with previous ischemic stroke and without known
prior AF and whether it could stratify poststroke patients into
different risk groups for incident AF.
Methods
The data that support the ﬁndings of this study are available
from the corresponding author on reasonable request. This
longitudinal cohort study was based on a national hospital-
ization database in France covering hospital care across the
entire population. In France, each hospital discharge, whether
from a public or a private hospital, must be registered in the
National Hospital Discharge Database (PMSI [Programme de
Medicalisation des Systemes d’Information]).14 A standard-
ized discharge summary is collected for every hospital stay in
France and categorized into a single medical or surgical
diagnosis-related group based on the diagnosis and proce-
dures coded, inspired by the US Medicare system.15 Since
2001, a unique patient identiﬁcation number has made it
possible to link multiple hospital stays corresponding to a
single patient without revealing his or her identity. Since
2004, each hospital’s budget has been linked to the medical
activity described in this speciﬁc program, which compiles
discharge abstracts related to all admissions for inpatients in
the 1546 French healthcare facilities. The International
Classiﬁcation of Diseases, Tenth Revision (ICD-10) has been
used to code discharge diagnoses since 1996. The main
outcome measure was the rate of incident AF.
Data for all patients admitted with ischemic stroke in
France from January 2008 to December 2012 were collected
from the PMSI using the annually updated versions of the ICD-
10 for the years 2008–2012. The reliability of PMSI data has
already been assessed16 and used previously to study
patients with stroke and AF.17,18
The medical information contained in the database is
anonymous and protected by professional conﬁdentiality.
Consequently, ethics review was not required. Patient consent
was not sought. The study was conducted retrospectively,
patients were not involved in its conduct, and there was no
impact on their care. This type of study was approved by the
institutional review board of the Pole Coeur Thorax Vaisseaux
from the Trousseau University Hospital (Tours, France) on
December 1, 2015, and registered as a clinical audit.
Procedures for data collection and management were
approved by the Conseil National de l’Informatique et des
Libertes, the independent national ethics committee protect-
ing human rights in France, which ensures that all information
is kept conﬁdential and anonymous (authorization no.
1749007). The study included adults (aged ≥18 years) with
a diagnosis of acute ischemic stroke (code I63 and its
subsections using ICD-10) coded as the primary diagnosis (ie,
the health problem that justiﬁed admission to hospital), the
related diagnosis (ie, potential chronic disease or health state
during hospital stay), or the signiﬁcantly associated diagnosis
(ie, comorbidity or associated complication) who were hospi-
talized between January 1, 2008, and December 31, 2012. We
Clinical Perspective
What Is New?
• The C2HEST score, a simple clinical risk stratiﬁcation
model, has been proposed to predict incident atrial
ﬁbrillation among Asian patients.
• In the nationwide analysis of 240 459 patients with
previous ischemic stroke in France, we found that the
C2HEST score performed well in discriminating the individ-
ual risk of developing incident atrial ﬁbrillation.
What Are the Clinical Implications?
• The simple C2HEST score has potential to be used as a risk
stratiﬁcation tool for decision making in relation to a
screening strategy for atrial ﬁbrillation in poststroke non-
Asian patients.
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performed an analysis restricted to the patients seen after
2009, meaning that all patients had at least 1 year in which
previous events were recorded to establish history of previous
AF and comorbidities. Patients with no diagnosis of AF were
considered to have sinus rhythm. Of note, asymptomatic
cerebrovascular diseases and sequelae of stroke have different
codes (I65, I66, and I69 with subdivisions) to be distinguished
from acute strokes and were not included in our analysis. We
calculated the CHA2DS2-VASc (congestive heart failure,
hypertension, age ≥75 [doubled], diabetes mellitus, stroke
[doubled], vascular disease, age 65 to 74 years, and female
sex) and C2HEST scores, as described previously.
9,19 Because
both hypo- and hyperthyroidism have been associated with
AF,20,21 we used a more general item of thyroid disease instead
of hyperthyroidism when calculating the C2HEST score. We also
performed a sensitivity analysis with the C2HEST score using
hyperthyroidism only. We also calculated a modiﬁed Framing-
ham risk score based on its initial description.22
Statistical Analysis
Qualitative variables were described using counts and percent-
ages, and continuous quantitative variables were described as
meanSD or median (interquartile range). Comparisons were
made using parametric or nonparametric tests, as appropriate:
The Wilcoxon signed rank and Kruskal–Wallis tests were used
for comparing values between 2 independent groups, and the
v2 test was used to compare categorical data. The population of
individuals seen with ischemic stroke without prior AF was
analyzed by calculating incidence rates of new-onset AF and by
multivariable Cox regression models. A proportional hazards
model was used to identify independent characteristics asso-
ciated with the occurrence of AF during follow-up. Receiver
operating characteristic curves were constructed, and Harrell C
indexes (ie, area under the curve) were calculated as a measure
of model performance and compared using the DeLong test.
Integrated discriminatory improvement and net reclassiﬁcation
improvement were calculated according to the methods
described by Pencina et al23 to assess the discrimination and
reclassiﬁcation performance of the scores. Clinical usefulness
and net beneﬁt of the C2HEST score in comparison to the
CHA2DS2-VASc score and the Framingham risk score were
estimated using decision curve analysis.24,25 In all analyses,
P<0.05 was considered statistically signiﬁcant. All analyses
were performed using JMP 9.0.1 (SAS Institute) and STATA
v12.0 (StataCorp).
Results
A total of 240 459 patients were included in the analysis.
During follow-up, 14 095 patients developed incident AF,
which give us 158 302 person-years of experience (mean
follow-up of 7.911.5 months). Baseline characteristics are
presented in Table 1. Patients with AF were older than those
without AF (P<0.0001), and more were female (P<0.0001).
The prevalence of each comorbidity was higher in AF patients,
including hypertension, diabetes mellitus, coronary arterial
disease, valve disease, hyperlipidemia, vascular disease,
chronic obstructive pulmonary disease, renal dysfunction,
thyroid disease, and HF (P<0.0001, respectively). Patients
who developed AF had higher CHA2DS2-VASc scores at
baseline than those who did not develop AF (P<0.0001).
Results of the Cox multivariable regression analysis for
incident AF are shown in Table 2. On multivariable analysis,
HF, age ≥75 years, coronary arterial disease, valve disease,
chronic obstructive pulmonary disease, hypertension, and
renal dysfunction were shown to be independently related to
the development of incident AF. HF and age ≥75 years were
the most potent risk factors for incident AF, with hazard ratios
(HRs) >2.0.
The incident rate of AF increased signiﬁcantly with higher
C2HEST scores (Figure 1). The HRs for incident AF increased
with higher score and risk group (Figure 2). When divided into
3 groups by baseline C2HEST score, annual incidence rates
were 3.19% in the low-risk group (0 or 1 point), 7.15% in the
medium-risk group (2 or 3 points), and 14.64% in the high-risk
group (≥4 points). The Kaplan–Meier curves for the 3 risk
categories showed a graded increased risk for incident AF
across risk groups (log-rank P<0.0001; Figure 3).
The C2HEST score showed good discriminative ability with a
C index of 0.734 (95% CI, 0.732–0.736), which was signiﬁcantly
better than the CHA2DS2-VASc score (0.703; 95% CI, 0.701–
0.704; P<0.0001) and the Framingham risk score (0.720; 95%
CI, 0.718–0.722; P<0.0001; Figure 4A). These results with the
C2HEST score using an item of thyroid disease including hypo-
or hyperthyroidism were marginally better than the sensitivity
analysis with the score calculated using hyperthyroidismonly (C
index: 0.716; 95% CI, 0.714–0.718). The discriminative ability
of the C2HEST score was also assessed with regard to sex,
showing satisfactory results in both men (C index: 0.741; 95%
CI, 0.735–0.747) and women (C index: 0.724; 95% CI, 0.718–
0.729). Among elderly patients (aged ≥75 years), the C2HEST
score could also discriminate for different risk strata in relation
to incident AF (C index: 0.694; 95% CI, 0.689–0.700; for
patients aged <75 years: C index: 0.735; 95%CI, 0.728–0.743).
The C2HEST score had positive net reclassiﬁcation
improvement and integrated discriminatory improvement
compared with the CHA2DS2-VASc score (23.6% [P<0.0001]
and 31.0% [P<0.0001], respectively) and the Framingham risk
score (6.7% [P<0.0001] and 12.0% [P<0.0001], respectively).
Using decision curve analysis, the C2HEST score showed
better clinical usefulness compared with the CHA2DS2-VASc
and Framingham risk scores (Figure 4B).
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Discussion
This study is the ﬁrst to externally validate the newly
established C2HEST score, a simple risk prediction model
for incident AF, in a European cohort by using a nationwide
(French) hospital-based white European population admitted
with ischemic stroke. We found that the C2HEST score
performed well in discriminating the individual risk of
developing incident AF in a white European population
hospitalized with previous stroke. Given that poststroke
patients at high risk incident AF should be targeted for more
comprehensive screening, this simple score has the potential
to be used as a risk-stratiﬁcation tool for decision making in
relation to a screening strategy for AF in poststroke patients.
The predictive performance of this risk score was statis-
tically better than that of the CHA2DS2-VASc and Framingham
risk scores, which have previously been shown to be useful for
AF prediction.22,26,27 As demonstrated by integrated discrim-
inatory improvement and net reclassiﬁcation improvement
analyses, compared with CHA2DS2-VASc, 23.6% more of the
studied population was correctly classiﬁed into the right risk
group28 and 31.0% more model sensitivity (with no loss of
speciﬁcity) was obtained by the C2HEST score.
29 Compared
with the Framingham score, 6.7% of population was correctly
reclassiﬁed and model sensitivity was increased by 12.0%
with the C2HEST score.
The independent risk factors in this newly established
C2HEST score were most common comorbidities among
community and hospital-based populations. The deﬁnitions of
these risk factors are relatively clear and support accessible
and easy evaluation of patients’ risk of developing incident AF.
On multivariable analysis, we found multiple independent
risk factors for incident AF in our cohort, including coronary
arterial disease, chronic obstructive pulmonary disease,
hypertension, age ≥75 years, HF, and thyroid disease, all of
which are constituents of the C2HEST score. HF and age
≥75 years had higher HRs (>2), which were also considered
major risk factors for incident AF in the C2HEST score.
9
Nevertheless, some differences exist in our study compared
with the original Asian cohort describing the C2HEST score.
9
Because both hypo- and hyperthyroidism have been associ-
ated with AF,20,21 we used a more general item of thyroid
disease instead of hyperthyroidism when calculating the
C2HEST score, and this change showed slightly better
predictive ability. We found that renal dysfunction was a risk
factor in the present study but not an independent risk factor
in Asian cohorts.9 This result may be because of the different
risk factor proﬁles among the different populations. In the
European population, renal dysfunction may be a stronger risk
factor for incident AF than in Asian patients.30 For example, 2
studies from European populations reported renal impairment
as an independent risk factor for incident AF, with HRs
between 2.5 to 2.6.31,32 In contrast, a report on a large cohort
of 500 000 Asian patients found that renal dysfunction was
not an independent risk factor (HR: 1.58; 95% CI, 0.78–
3.20).10 In another cohort from Taiwan (n=15 947), renal
dysfunction showed an association with incident AF but with a
relatively lower HR (1.46; 95% CI, 1.31–1.61)33 compared
with that reported in European populations. In this Taiwanese
cohort, hemodialysis was analyzed as “renal dysfunction” but
is a substantially more severe stage of this disease.33
We found the C2HEST score performed well in discrimi-
nating individual risk of incident AF, and this ability was
consistent in both sexes and in different age strata. When
divided into different point ranges, incidence of AF increased
with increasing C2HEST scores. In addition, incidence of AF
increased signiﬁcantly with higher risk categorization, with an
incident rate of 146.4 per 1000 person-years in the high-risk
group (score ≥4). The C index for this score was also good in
our white European cohort, consistent with the original
derivation study from Asia.9
Several previously proposed risk models for predicting
incident AF were derived from Western populations, including
the Framingham risk score (Framingham Heart Survey),22 the
Table 1. Baseline Characteristics of 240 459 Patients
Included in the Study
Characteristics
Patients
Without AF
(n=226 364)
Patients With
Incident AF
(n=14 095) P Value
Age, y, meanSD 70.815.7 77.610.6 <0.0001
Male sex, n (%) 119 098 (53.0) 7013 (50.0) <0.0001
Medical history, n (%)
Hypertension 141 045 (62.3) 11 745 (83.3) <0.0001
Diabetes mellitus 50 977 (22.5) 4083 (29.0) <0.0001
Coronary
arterial disease
39 652 (17.5) 4969 (35.3) <0.0001
Valve disease 15 121 (6.7) 2780 (19.7) <0.0001
Hyperlipidemia 69 428 (30.7) 5793 (41.1) <0.0001
Vascular disease 70 636 (31.2) 6907 (49.0) <0.0001
COPD 35 320 (15.6) 3661 (26.0) <0.0001
Renal dysfunction 38 618 (17.1) 5393 (38.3) <0.0001
Hyperthyroidism 3355 (1.5) 646 (4.6) <0.0001
Thyroid disease 19 720 (8.7) 2525 (17.9) <0.0001
HF 33 162 (14.7) 6261 (44.4) <0.0001
CHA2DS2-VASc
score,
median (IQR)
5 (2) 6 (2) <0.0001
Thyroid disease comprises hypo- and hyperthyroidism. CHA2DS2-VASc score is
composed of congestive heart failure, hypertension, age ≥75 (doubled), diabetes
mellitus, stroke (doubled), vascular disease, age 65 to 74 years, and female sex. AF
indicates atrial ﬁbrillation; COPD, chronic obstructive pulmonary disease; HF, heart
failure; IQR, interquartile range.
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ARIC (Atherosclerosis Risk in Communities) score,34 the
CHARGE-AF (Cohorts for Heart and Aging Research in
Genomic Epidemiology–Atrial Fibrillation) score,35 and the
STAF (Score for the Targeting of Atrial Fibrillation) score.36
These risk scores had good discrimination for incident AF
in their original studies; however, they require many instru-
mental and laboratory variables that might not be easily
accessed in everyday practice. Furthermore, such com-
plexity limits their daily application for operationalizing risk
assessment in the real world, although they had good C
indexes in the original studies.37 Compared with the Fram-
ingham risk score (slightly modiﬁed), the C2HEST score
showed superiority for AF prediction in this poststroke patient
population.
The CHADS2, CHA2DS2-VASc, and HATCH (hypertension,
age ≥75 years, transient ischemic attack or stroke [2 points],
chronic obstructive pulmonary disease and HF [2 points])
scores also showed predictive capacity for incident AF in
previous studies.26,38 However, these scores were not derived
for this purpose. Some components of these scores may not
be risk factors for incident AF, such as female sex in the
CHA2DS2-VASc score. In addition, stroke or transient
ischemic attack does not increase an individual’s risk of
developing AF but may be an indicator of undiagnosed AF.
Nevertheless, we previously compared the performance of
these scores in predicting incident AF and demonstrated the
better discriminative ability of the new C2HEST score.
9
In the present study, all patients had a history of ischemic
stroke and thus should be candidates for screening of silent
AF.12,39 In the 2016 AF guidelines from the European Society
of Cardiology, screening for AF using short-term ECG
recording followed by continuous ECG monitoring for at least
72 hours is recommended in patients with ischemic stroke
(class I recommendation with level B evidence), and additional
ECG monitoring by long-term noninvasive ECG monitors or
implanted loop recorders may be considered to document
silent AF (class IIa recommendation with level B evidence).12
However, only a limited number of patients receive AF
screening because of the uncertainty about cost-effectiveness
and the lack of robust evidence justifying the utility of AF
screening.40
In our study, we found that patients with a C2HEST score ≥4
had extremely high risk of developing incident AF (14.6% per
person-year), justifying the need for more intensive ECG
monitoring for silent or asymptomatic AF.39 The availability of
simple risk stratiﬁcation may lead to a more effective and cost-
effective, selective, opportunistic screening approach,41,42
targeting patients at high risk of incident AF and its sequelae
and supporting better adherence to guideline recommenda-
tions for AF screening. For instance, patients with extremely
high C2HEST scores should receive more intensive heart-rate
monitoring, such as 1 to 2 weeks of Holter monitoring or an
implantable loop recorder.
In the STROKESTOP (Massive Screening for Untreated
Atrial Fibrillation) study, screening for asymptomatic AF in 75-
or 76-year-old individuals was found to be cost-effective.43
With a simple risk-assessment model, it would be possible to
increase efﬁciency by targeting a more intensive screening
Table 2. HRs of Risk Factors for Incident AF
Risk Factors
Univariate Analysis Multivariable Analysis
HR 95% CI P Value HR 95% CI P Value
HF 2.99 2.89–3.09 <0.0001 2.21 2.13–2.30 <0.0001
Age ≥75 y 2.54 2.45–2.63 <0.0001 2.11 2.04–2.19 <0.0001
Coronary arterial disease 1.70 1.64–1.76 <0.0001 1.09 1.05–1.13 <0.0001
Valve disease 2.26 2.18–2.36 <0.0001 1.42 1.36–1.48 <0.0001
Thyroid disease 1.71 1.64–1.79 <0.0001 1.36 1.31–1.43 <0.0001
COPD 1.42 1.36–1.47 <0.0001 1.18 1.14–1.22 <0.0001
Hypertension 1.90 1.81–1.98 <0.0001 1.34 1.27–1.40 <0.0001
Renal dysfunction 2.02 1.96–2.09 <0.0001 1.21 1.17–1.26 <0.0001
Hyperlipidemia 1.06 1.03–1.10 0.0005 0.87 0.84–0.90 <0.0001
Male sex 0.83 0.80–0.86 <0.0001 0.99 0.95–1.02 0.38
Diabetes mellitus 1.07 1.04–1.11 <0.0001 0.95 0.91–0.98 0.002
Vascular disease 1.42 1.37–1.46 <0.0001 0.93 0.90–0.97 <0.0001
Thyroid disease comprises hypo- and hyperthyroidism. CHA2DS2-VASc score is composed of congestive heart failure, hypertension, age ≥75 (doubled), diabetes mellitus,
stroke (doubled), vascular disease, age 65 to 74 years, and female sex. AF indicates atrial ﬁbrillation; COPD, chronic obstructive pulmonary disease; HF, heart failure; HR, hazard
ratio.
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approach among those at higher risk of developing incident
AF.44 In this study, we demonstrated that the C2HEST score
could further discriminate those at-risk elderly patients (aged
≥75 years) for AF. By initially calculating an individual C2HEST
score, conducting a more focused and cost-effective screen-
ing strategy may become more feasible.
Figure 1. Prevalence of the C2HEST scores and incident rate of atrial ﬁbrillation (AF). *Per
1000 person-years.
Figure 2. Annual incidence of atrial ﬁbrillation (AF) by C2HEST score. *Per 1000 person-years.
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Strengths and Limitations
This study is the ﬁrst external validation of theC2HEST score in a
large, nationwide, hospital-based, European population
(French) with prior stroke history. We found that the C2HEST
score performed satisfactorily in evaluating the individual risk of
developing incident AF after ischemic stroke, whichmay allow a
targeted and tailored screening strategy in this population.
Nevertheless, this study has some limitations. First, this
hospital-based cohort study in France may not represent the
general population. Incidental AF might be marginally underes-
timated if it were identiﬁed in only some outpatients during
follow-up. Considering the way in which a history of AF might
have been determined, a washout period of 1 year might be too
short, and there is also a risk of underdiagnosis for prior AF in
our population. We did not compare the performance of the
C2HEST score with other previously established scores, such as
the ARIC, CHARGE-AF, or STAF scores, because some variables
were unavailable in our data set to calculate those scores. For
comparison with the Framingham risk score, we used a slightly
modiﬁed model based on the original model, and this change
may have introduced some difference from the original. Finally,
some variables are known to inﬂuence the odds of detecting AF,
such as chronic kidney disease, but are not included in the
C2HEST score. By including hyperthyroidism, the score may be
biased for identiﬁcation of circumstantial and transient causes
of AF that may not be substantially relevant in terms of the
decision to anticoagulate.
Conclusion
The C2HEST score performed well in discriminating the
individual risk of developing incident AF in a white European
population hospitalized with previous stroke. This simple
score has the potential to be used as a risk-stratiﬁcation tool
for decision making in relation to a screening strategy for AF
in poststroke patients.
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